Lysogene宣布与魏茨曼科学研究所的研究合作

Lysogene宣布与魏茨曼科学研究所的研究合作150150Lysogene
  • 新型AAV基因治疗G亚搏全站app下载BA1突变的神经病戈谢病和帕金森病

法国巴黎 - 2020年7月1日 - Lysogene(FR0013233475 - LYS),一期3基因治疗平台公司亚搏全站app下载针对中枢神经系统(CNS)疾病,今天宣布,该公司已与耶达研究和开发elopment有限公司,魏茨曼科学研究所的商业部门的合作研究协议。

该协议涉及Lysogene和Anthony Futerman教授在魏茨曼科学研究所实验室之间的协作,以开发用于神经型戈谢病,帕金森病,以及与GBA1基因的突变相关的其他疾病的新的AAV基因治疗方法的目的亚搏全站app下载。根据协议的条款,Lysogene将提供AAV载体的设计和生产的专业企业,同时Futerman教授的实验室将提供葡糖脑苷脂酶的提高了生物特性的变体,并进行生物证据和概念研究。Lysogene拥有独家选项许可程序。

拉尔夫·劳费尔,首席科学官Lysogene说过:“我们很高兴能与鞘脂生物学领域的顶级专家Futerman教授展开这项研究合作。魏茨曼研究所是世界领先的多学科研究机构之一,也是众多突破性医学发现和技术应用的来源。Lysogene公司正在开发单基因性神经系统疾亚搏全站app下载病的基因治疗方法,包括神经病溶酶体储存疾病。这项合作与Lysogene公司的战略完美契合,为开发一种罕见的溶酶体疾病的新疗法提供了机会,并有可能扩展到患者数量更大的神经系统疾病,比如帕金森病。”

关于Lysogene

Lysogene是一家专注于亚搏全站app下载治疗中枢神经系统孤儿病的基因治疗公司。该公司建立了一种独特的能力,能够安全有效地为中枢神经系统提供基因治疗,以治疗溶酶体疾病和中枢神经系统的其他遗传疾病。与Sarepta Therapeutics, Inc.合作的MPS IIIA 2/3期临床试验正在进行中,针对GM1神经节sidosis的1/3期临床试验正在准备中。亚博登录首页根据Lysogene和Sarepta Therapeutics, Inc.签署的协议,Sarepta Therapeutics, Inc.将拥有LYS-SAF302在美国和欧洲以外市场的独家商业权利;Lysogene将继续保持其在欧洲的商业独家经营权。Lysogene公司还与一位学术伙伴合作,研究脆性X染色体综合征的基因治疗方法。脆性X染色体综合征是一种与自闭症相关的遗传亚搏全站app下载病。www.astridbowlby.com。

前瞻性声明

本新闻稿可能包含某些前瞻性声明,预测和估计相对于Lysogene的临床试验,临床试验数据公布,临床开发计划,预期未来的活动和Lysogene现金跑道。Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

这份新闻稿是用法文和英文编写的。两个文本如有任何差异,应以法文本为准。

联系人

斯特凡杜兰特DES奥尔努瓦首席财务官

stephane.durant-des-aulnois@lysogene.com

+ 33 1 41 43 03 99

Lysogene COVID-19更新

保持联系

不要犹豫,如果你需要更多的帮助与我们联系。